|
1.Bray, F., et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 2018. 68(6): p. 394-424.
2.Jiang, W.G., et al. Tissue invasion and metastasis: Molecular, biological and clinical perspectives. in Seminars in cancer biology. 2015. Elsevier.
3.Shen, D.-W., et al., Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacological reviews, 2012. 64(3): p. 706-721.
4.Pabla, N. and Z. Dong, Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney international, 2008. 73(9): p. 994-1007.
5.Forrester, S.J., et al., Reactive oxygen species in metabolic and inflammatory signaling. Circulation research, 2018. 122(6): p. 877-902.
6.Zorov, D.B., M. Juhaszova, and S.J. Sollott, Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiological reviews, 2014. 94(3): p. 909-950.
7.Liou, G.-Y. and P. Storz, Reactive oxygen species in cancer. Free radical research, 2010. 44(5): p. 479-496.
8.Rahal, A., et al., Oxidative stress, prooxidants, and antioxidants: the interplay. BioMed research international, 2014. 2014.
9.Montero, A.J. and J. Jassem, Cellular redox pathways as a therapeutic target in the treatment of cancer. Drugs, 2011. 71(11): p. 1385-1396.
10.Ren, X., et al., Redox signaling mediated by thioredoxin and glutathione systems in the central nervous system. Antioxidants & redox signaling, 2017. 27(13): p. 989-1010.
11.Benhar, M., et al., Dual targeting of the thioredoxin and glutathione systems in cancer and HIV. The Journal of clinical investigation, 2016. 126(5): p. 1630-1639.
12.Estrela, J.M., A. Ortega, and E. Obrador, Glutathione in cancer biology and therapy. Critical reviews in clinical laboratory sciences, 2006. 43(2): p. 143-181.
13.Forman, H.J., H. Zhang, and A. Rinna, Glutathione: overview of its protective roles, measurement, and biosynthesis. Molecular aspects of medicine, 2009. 30(1-2): p. 1-12.
14.Lushchak, V.I., Glutathione homeostasis and functions: potential targets for medical interventions. Journal of amino acids, 2012. 2012.
15.Yang, H., et al., The role of cellular reactive oxygen species in cancer chemotherapy. Journal of Experimental & Clinical Cancer Research, 2018. 37(1): p. 266.
16.Ju, E., et al., Copper (II)–graphitic carbon nitride triggered synergy: Improved ROS generation and reduced glutathione levels for enhanced photodynamic therapy. Angewandte Chemie, 2016. 128(38): p. 11639-11643.
17.You, B.R. and W.H. Park, Arsenic trioxide induces human pulmonary fibroblast cell death via increasing ROS levels and GSH depletion. Oncology reports, 2012. 28(2): p. 749-757.
18.Lu, J. and A. Holmgren, The thioredoxin antioxidant system. Free Radical Biology and Medicine, 2014. 66: p. 75-87.
19.Lu, J., E.-H. Chew, and A. Holmgren, Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proceedings of the national academy of sciences, 2007. 104(30): p. 12288-12293.
20.Zhang, J., et al., Targeting the thioredoxin system for cancer therapy. Trends in pharmacological sciences, 2017. 38(9): p. 794-808.
21.Urig, S. and K. Becker. On the potential of thioredoxin reductase inhibitors for cancer therapy. in Seminars in cancer biology. 2006. Elsevier.
22.Tonissen, K.F. and G. Di Trapani, Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy. Molecular nutrition & food research, 2009. 53(1): p. 87-103.
23.McCall, R., et al., Dual targeting of the cancer antioxidant network with 1, 4-naphthoquinone fused Gold (I) N-heterocyclic carbene complexes. Chemical science, 2017. 8(9): p. 5918-5929.
24.Gao, F., et al., Au nanoclusters and photosensitizer dual loaded spatiotemporal controllable liposomal nanocomposites enhance tumor photodynamic therapy effect by inhibiting thioredoxin reductase. Advanced healthcare materials, 2017. 6(7): p. 1601453.
25.Du, Y., et al., Glutathione and glutaredoxin act as a backup of human thioredoxin reductase 1 to reduce thioredoxin 1 preventing cell death by aurothioglucose. Journal of Biological Chemistry, 2012. 287(45): p. 38210-38219.
26.Harris, I.S., et al., Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer cell, 2015. 27(2): p. 211-222.
27.Maeda, H., et al., Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine. Cell Death & Differentiation, 2004. 11(7): p. 737-746.
28.Fath, M.A., et al., Enhancement of carboplatin-mediated lung cancer cell killing by simultaneous disruption of glutathione and thioredoxin metabolism. Clinical Cancer Research, 2011. 17(19): p. 6206-6217.
29. Jakupec, M.A., et al., Antitumour metal compounds: more than theme and variations. Dalton transactions, 2008(2): p. 183-194.
30. Zhao, G. and H. Lin, Metal complexes with aromatic N-containing ligands as potential agents in cancer treatment. Current Medicinal Chemistry-Anti-Cancer Agents, 2005. 5(2): p. 137-147.
31. Frezza, M., et al., Novel metals and metal complexes as platforms for cancer therapy. Current pharmaceutical design, 2010. 16(16): p. 1813-1825.
32. Cohen, S.M., New approaches for medicinal applications of bioinorganic chemistry. Current opinion in chemical biology, 2007. 11(2): p. 115-120.
33. Fricker, S.P., Metal based drugs: from serendipity to design. Dalton transactions, 2007(43): p. 4903-4917.
34. Hambley, T.W., Developing new metal-based therapeutics: challenges and opportunities. Dalton Transactions, 2007(43): p. 4929-4937.
35. Orvig, C. and M.J. Abrams, Medicinal inorganic chemistry: introduction. Chemical Reviews, 1999. 99(9): p. 2201-2204.
36. Ott, I. and R. Gust, Non platinum metal complexes as anti‐cancer drugs. Archiv der Pharmazie: An International Journal Pharmaceutical and Medicinal Chemistry, 2007. 340(3): p. 117-126.
37. Rosenberg, B., et al., Platinum compounds: a new class of potent antitumour agents. Nature, 1969. 222(5191): p. 385-386.
38. Basu, A. and S. Krishnamurthy, Cellular responses to Cisplatin-induced DNA damage. Journal of nucleic acids, 2010. 2010.
39. Cepeda, V., et al., Biochemical mechanisms of cisplatin cytotoxicity. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 2007. 7(1): p. 3-18.
40. Mjos, K.D. and C. Orvig, Metallodrugs in medicinal inorganic chemistry. Chemical reviews, 2014. 114(8): p. 4540-4563.
41. Dasari, S. and P.B. Tchounwou, Cisplatin in cancer therapy: molecular mechanisms of action. European journal of pharmacology, 2014. 740: p. 364-378.
42. Goodsell, D.S., The molecular perspective: cisplatin. Stem cells, 2006. 24(3): p. 514.
43. Jungwirth, U., et al., Anticancer activity of metal complexes: involvement of redox processes. Antioxidants & redox signaling, 2011. 15(4): p. 1085-1127.
44. Frezza, M., et al., Novel metals and metal complexes as platforms for cancer therapy. Current pharmaceutical design, 2010. 16(16): p. 1813-1825.
45. Zou, T., et al., Chemical biology of anticancer gold (III) and gold (I) complexes. Chemical Society Reviews, 2015. 44(24): p. 8786-8801.
46. Ndagi, U., N. Mhlongo, and M.E. Soliman, Metal complexes in cancer therapy–an update from drug design perspective. Drug design, development and therapy, 2017. 11: p. 599.
47. Baughman, R.H., A.A. Zakhidov, and W.A. De Heer, Carbon nanotubes--the route toward applications. science, 2002. 297(5582): p. 787-792.
48. Geim, A.K. and K.S. Novoselov, The rise of graphene, in Nanoscience and technology: a collection of reviews from nature journals. 2010, World Scientific. p. 11-19.
49. Tao, S., et al., Carbonized Polymer Dots: A Brand New Perspective to Recognize Luminescent Carbon-Based Nanomaterials. The Journal of Physical Chemistry Letters, 2019. 10(17): p. 5182-5188.
50. Wang, X., et al., Bandgap‐Like strong fluorescence in functionalized carbon nanoparticles. Angewandte Chemie International Edition, 2010. 49(31): p. 5310-5314.
51. Zhu, S., et al., Highly photoluminescent carbon dots for multicolor patterning, sensors, and bioimaging. Angewandte Chemie International Edition, 2013. 52(14): p. 3953-3957.
52. Zhang, Z., et al., Graphene quantum dots: an emerging material for energy-related applications and beyond. Energy & Environmental Science, 2012. 5(10): p. 8869-8890.
53. Peng, Z., et al., Carbon dots: biomacromolecule interaction, bioimaging and nanomedicine. Coordination Chemistry Reviews, 2017. 343: p. 256-277.
54. Wang, H., Q. Chen, and S. Zhou, Carbon-based hybrid nanogels: a synergistic nanoplatform for combined biosensing, bioimaging, and responsive drug delivery. Chemical Society Reviews, 2018. 47(11): p. 4198-4232.
55. Wang, H., et al., Biocompatible PEG‐chitosan@ carbon dots hybrid nanogels for two‐photon fluorescence imaging, near‐infrared light/pH dual‐responsive drug carrier, and synergistic therapy. Advanced Functional Materials, 2015. 25(34): p. 5537-5547.
56. Wang, H., et al., Responsive polymer–fluorescent carbon nanoparticle hybrid nanogels for optical temperature sensing, near-infrared light-responsive drug release, and tumor cell imaging. Nanoscale, 2014. 6(13): p. 7443-7452.
57. Wang, H., et al., Magnetic/NIR-thermally responsive hybrid nanogels for optical temperature sensing, tumor cell imaging and triggered drug release. Nanoscale, 2014. 6(21): p. 13001-13011.
58. Fulda, S., L. Galluzzi, and G. Kroemer, Targeting mitochondria for cancer therapy. Nature reviews Drug discovery, 2010. 9(6): p. 447-464.
59. Phillips, M.J. and G.K. Voeltz, Structure and function of ER membrane contact sites with other organelles. Nature reviews Molecular cell biology, 2016. 17(2): p. 69.
60. Wallace, D.C., Mitochondria and cancer. Nature Reviews Cancer, 2012. 12(10): p. 685-698.
61. Wang, M. and R.J. Kaufman, The impact of the endoplasmic reticulum protein-folding environment on cancer development. Nature Reviews Cancer, 2014. 14(9): p. 581-597.
62. Chen, W.H., G.F. Luo, and X.Z. Zhang, Recent Advances in Subcellular Targeted Cancer Therapy Based on Functional Materials. Adv Mater, 2019. 31(3): p. e1802725.
63. Gao, P., et al., Boosting Cancer Therapy with Organelle-Targeted Nanomaterials. ACS Appl Mater Interfaces, 2019. 11(30): p. 26529-26558.
64. Ashley, C.E., et al., The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nature materials, 2011. 10(5): p. 389-397.
65. Marrache, S., R.K. Pathak, and S. Dhar, Detouring of cisplatin to access mitochondrial genome for overcoming resistance. Proceedings of the National Academy of Sciences, 2014. 111(29): p. 10444-10449.
66. Zhou, W., et al., Redox-triggered activation of nanocarriers for mitochondria-targeting cancer chemotherapy. Nanoscale, 2017. 9(43): p. 17044-17053.
67. Gong, N., et al., Carbon-dot-supported atomically dispersed gold as a mitochondrial oxidative stress amplifier for cancer treatment. Nature nanotechnology, 2019. 14(4): p. 379-387.
68. Bao, Y.-W., et al., Endoplasmic reticulum-targeted phototherapy using one-step synthesized trace metal-doped carbon-dominated nanoparticles: Laser-triggered nucleolar delivery and increased tumor accumulation. Acta biomaterialia, 2019. 88: p. 462-476.
69. Smith, R.A., et al., Delivery of bioactive molecules to mitochondria in vivo. Proceedings of the National Academy of Sciences, 2003. 100(9): p. 5407-5412.
70. Biswas, S., et al., Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium-PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo. Journal of controlled release, 2012. 159(3): p. 393-402.
71. Wang, B., et al., A mitochondria-targeted fluorescent probe based on TPP-conjugated carbon dots for both one-and two-photon fluorescence cell imaging. Rsc Advances, 2014. 4(91): p. 49960-49963.
72. Hua, X.-W., et al., Carbon quantum dots with intrinsic mitochondrial targeting ability for mitochondria-based theranostics. Nanoscale, 2017. 9(30): p. 10948-10960.
73. Bao, Y.-W., et al., Platinum-doped carbon nanoparticles inhibit cancer cell migration under mild laser irradiation: Multi-organelle-targeted photothermal therapy. Biomaterials, 2018. 183: p. 30-42.
74. Gangopadhayay, A.K. and A. Chakravorty, Charge transfer spectra of some gold (III) complexes. The Journal of Chemical Physics, 1961. 35(6): p. 2206-2209.
75. Wei, H., et al., Nucleobase− metal hybrid materials: Preparation of submicrometer-scale, spherical colloidal particles of adenine− gold (III) via a supramolecular hierarchical self-assembly approach. Chemistry of materials, 2007. 19(12): p. 2987-2993.
76. Zhou, P., et al., Supramolecular self-assembly of nucleotide–metal coordination complexes: From simple molecules to nanomaterials. Coordination Chemistry Reviews, 2015. 292: p. 107-143.
77. Mathlouthi, M., A.-M. Seuvre, and J.L. Koenig, FT-IR and laser-Raman spectra of adenine and adenosine. Carbohydrate research, 1984. 131(1): p. 1-15.
78. Tian, Z., B. Tian, and J. Zhang, Synthesis and characterization of new rhodamine dyes with large Stokes shift. Dyes and Pigments, 2013. 99(3): p. 1132-1136.
79. Iqbal, M.S., et al., In vitro distribution of gold in serum proteins after incubation of sodium aurothiomalate and auranofin with human blood and its pharmacological significance. Biological trace element research, 2009. 130(3): p. 204-209.
80. Roberts, J.R., et al., Kinetics and mechanism of the reaction between serum albumin and auranofin (and its isopropyl analogue) in vitro. Inorganic chemistry, 1996. 35(2): p. 424-433.
81. Fan, C., et al., Enhancement of auranofin-induced lung cancer cell apoptosis by selenocystine, a natural inhibitor of TrxR1 in vitro and in vivo. Cell death & disease, 2014. 5(4): p. e1191-e1191.
82. Lee, S., S.M. Kim, and R.T. Lee, Thioredoxin and thioredoxin target proteins: from molecular mechanisms to functional significance. Antioxidants & redox signaling, 2013. 18(10): p. 1165-1207.
83. Tan, C., et al., Sulfuric acid assisted preparation of red-emitting carbonized polymer dots and the application of bio-imaging. Nanoscale research letters, 2018. 13(1): p. 1-6.
84. Bao, Y.-W., et al., Hyperthemia-promoted cytosolic and nuclear delivery of copper/carbon quantum dot-crosslinked nanosheets: multimodal imaging-guided photothermal cancer therapy. ACS applied materials & interfaces, 2018. 10(2): p. 1544-1555.
85. Shamsipur, M., et al., Resolving the multiple emission centers in carbon dots: from fluorophore molecular states to aromatic domain states and carbon-core states. The journal of physical chemistry letters, 2018. 9(15): p. 4189-4198.
86. Mane, G.P., et al., Preparation of Highly Ordered Nitrogen‐Containing Mesoporous Carbon from a Gelatin Biomolecule and its Excellent Sensing of Acetic Acid. Advanced Functional Materials, 2012. 22(17): p. 3596-3604.
87. Zhang, J., et al., Design and synthesis of nitrogen and sulfur co-doped porous carbon via two-dimensional interlayer confinement for a high-performance anode material for lithium-ion batteries. Journal of Materials Chemistry A, 2016. 4(16): p. 5802-5809.
88. Nie, H., et al., Carbon dots with continuously tunable full-color emission and their application in ratiometric pH sensing. Chemistry of Materials, 2014. 26(10): p. 3104-3112.
89. Song, L., et al., Microwave-assisted facile synthesis of yellow fluorescent carbon dots from o-phenylenediamine for cell imaging and sensitive detection of Fe 3+ and H 2 O 2. RSC advances, 2016. 6(21): p. 17704-17712.
90. Chen, H., et al., Gadolinium‐encapsulated graphene carbon nanotheranostics for imaging‐guided photodynamic therapy. Advanced Materials, 2018. 30(36): p. 1802748.
91. Liu, J., et al., One‐Step Hydrothermal Synthesis of Nitrogen‐Doped Conjugated Carbonized Polymer Dots with 31% Efficient Red Emission for In Vivo Imaging. Small, 2018. 14(15): p. 1703919.
92. Sayyah, S., et al., Chemical polymerization kinetics of poly-o-phenylenediamine and characterization of the obtained polymer in aqueous hydrochloric acid solution using K2Cr2O7 as oxidizing agent. International Journal of Polymer Science, 2014. 2014.
93. Li, D., et al., Synthesis of ternary graphene/molybdenum oxide/poly (p-phenylenediamine) nanocomposites for symmetric supercapacitors. RSC Advances, 2015. 5(119): p. 98278-98287.
94. Humpolicek, P., et al., Biocompatibility of polyaniline. Synthetic metals, 2012. 162(7-8): p. 722-727.
95. Kucekova, Z., et al., Colloidal polyaniline dispersions: antibacterial activity, cytotoxicity and neutrophil oxidative burst. Colloids and Surfaces B: Biointerfaces, 2014. 116: p. 411-417.
96. Almeida, M.V.d., et al., Synthesis and characterization of platinum (II) complexes from trifluoromethyl phenylenediamine, picoline and N-benzyl ethylenediamine derivatives. Journal of the Brazilian Chemical Society, 2006. 17(7): p. 1266-1273.
97. Gale, G.R., et al., Antitumor Action of Dichloro (4, 5–dimethyl–o–phenylenediamine–N, N') platinum (II). Proceedings of the Society for Experimental Biology and Medicine, 1973. 142(4): p. 1349-1354.
98. Basotra, M., S.K. Singh, and M. Gulati, Development and validation of a simple and sensitive spectrometric method for estimation of cisplatin hydrochloride in tablet dosage forms: application to dissolution studies. ISRN Analytical Chemistry, 2013. 2013.
99. Shaili, E., et al., Platinum (IV) dihydroxido diazido N-(heterocyclic) imine complexes are potently photocytotoxic when irradiated with visible light. Chemical Science, 2019. 10(37): p. 8610-8617.
100. Wang, Y.C., et al., Core–shell–corona micelle stabilized by reversible cross‐linkage for intracellular drug delivery. Macromolecular rapid communications, 2010. 31(13): p. 1201-1206.
101. Gao, G., et al., Mitochondria-targetable carbon quantum dots for differentiating cancerous cells from normal cells. Nanoscale, 2017. 9(46): p. 18368-18378.
102. Handy, D.E. and J. Loscalzo, Redox regulation of mitochondrial function. Antioxidants & redox signaling, 2012. 16(11): p. 1323-1367.
103. Mari, M., et al., Mitochondrial glutathione, a key survival antioxidant. Antioxidants & redox signaling, 2009. 11(11): p. 2685-2700.
104. Ribas, V., C. García-Ruiz, and J.C. Fernández-Checa, Glutathione and mitochondria. Frontiers in pharmacology, 2014. 5: p. 151.
105. Bernareggi, A., et al., Characterization of cisplatin-glutathione adducts by liquid chromatography-mass spectrometry evidence for their formation in vitro but not in vivo after concomitant administration of cisplatin and glutathione to rats and cancer patients. Journal of Chromatography B: Biomedical Sciences and Applications, 1995. 669(2): p. 247-263.
106. Marullo, R., et al., Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. PloS one, 2013. 8(11).
107. Kleih, M., et al., Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells. Cell death & disease, 2019. 10(11): p. 1-12.
108. Weinberg, F. and N.S. Chandel, Mitochondrial metabolism and cancer. Annals of the New York Academy of Sciences, 2009. 1177(1): p. 66-73.
109. Perry, S.W., et al., Mitochondrial membrane potential probes and the proton gradient: a practical usage guide. Biotechniques, 2011. 50(2): p. 98-115.
110. Ling, X., et al., Tumor-targeting delivery of hyaluronic acid–platinum (iv) nanoconjugate to reduce toxicity and improve survival. Polymer Chemistry, 2015. 6(9): p. 1541-1552.
111. Browning, R.J., et al., Drug delivery strategies for platinum-based chemotherapy. ACS nano, 2017. 11(9): p. 8560-8578.
112. Gao, P., et al., Boosting cancer therapy with organelle-targeted nanomaterials. ACS applied materials & interfaces, 2019. 11(30): p. 26529-26558.
|